COVID-19 Pfizer Information

X

Thanks for finding us at SABCS 2021

Who We Are and What We Do

​​​​​​​One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases


​​​​​​​Thank you for finding us at SABCS 2021

Who We Are and What We Do

​​​​​​​One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases

Opportunities To Connect


​​​​​​ ​​​​​​Connect with Pfizer
through our Contact Form


Find My U.S.
Field Medical Director

Connect with Pfizer

Please fill out the form below. A member from the team will respond accordingly.

By providing your email address, you agree to receive an email response from Pfizer to your inquiry. Your email address will only be used to respond to your inquiry. The information you submit will be governed by our Privacy Policy.

All fields marked with an asterisk ( *) are required.

Thank you for
contacting Pfizer.

A team member will respond to your inquiry.

Product Theater

Product Theater Invite

View Link

Add To Calendar

Add To Calendar

Upcoming Opportunities to Connect

Product Theater

Expert Perspectives on the Treatment of a Broad Range of Patients With HR+/HER2- Metastatic Breast Cancer

Friday, December 10, 2021 12:00 - 1:00 PM CT

Add To Calendar

Oral Presentations

Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial

Tuesday, December 7, 2021 7:45 - 10:45 AM

Add To Calendar

Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials

​​​​​​​Wednesday, December 8, 2021 9:45 - 10:00 AM

Add To Calendar

Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

​​​​​​​Thursday, December 9, 2021 9:45 - 10:00 AM

Add To Calendar

Medical Information Office Hours

Tuesday, December 7, 2021 at 10:00 - 11:00 AM EST and 3:00 - 4:00 PM EST

Add To Calendar

Wednesday, December 8, 2021 at 10:00 - 11:00 AM EST and 3:00 - 4:00 PM EST

Add To Calendar

Thursday, December 9, 2021 at 10:00 - 11:00 AM EST and 3:00 - 4:00 PM EST

Add To Calendar

Friday, December 10, 2021 at 10:00 - 11:00 AM EST and 3:00 - 4:00 PM EST

Add To Calendar

Highlights From Your Congress

 

ARV-471 Clinical Trial Contact

Please fill out the form below. A member from the Arvinas medical team will respond accordingly.

By providing your email address, you agree to receive an email response from Arvinas to your inquiry. Your email address will only be used to respond to your inquiry. The information you submit will be governed by our  Privacy Policy.

All fields marked with an asterisk ( *) are required.

Thank you for
contacting Arvinas.

A team member will respond to your inquiry.

 

Product Theater

What’s Of Interest

Focus on Health Equity

Get It Done - Cancer Screening Campaign

Pfizer Oncology Collaborating to Improve Patient Centricity

Scheduled Events

Product Theater


Session Title:
Expert Perspectives on the Treatment of a Broad Range of Patients With HR+/HER2- Metastatic Breast Cancer
Session Date and Time:
Friday, December 10, 2021
​​​​​​​12:00 - 1:00 pm (CT)

 

Oral Presentations


 Session Title:
Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial
Session Date and Time:
Tuesday, December 7, 2021
7:45 - 10:45 AM
Program #: GS1-07​​​


Session Title:
Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials
Session Date and Time:
Wednesday, December 8, 2021
9:45 - 10:00 AM​​​​​​​
Program #: GS2-05


Session Title:
Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial
Session Date and Time:
Thursday, December 9, 2021
9:45 - 10:00 AM​​​​​​​
Program #: GS3-05

Live U.S. Medical Information Office Hours


Tuesday, December 7, 2021 at 10:00 - 11:00 AM EST and 3:00 - 4:00 PM EST

Wednesday, December 8, 2021 at 10:00 - 11:00 AM EST and 3:00 - 4:00 PM EST

Thursday, December 9, 2021 at 10:00 - 11:00 AM EST and 3:00 - 4:00 PM EST

Friday, December 10, 2021 at 10:00 - 11:00 AM EST and 3:00 - 4:00 PM EST

 
 

Commitment To Oncology

X

PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.